Stockreport

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)  (TAK) 
PDF Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia VeraNDA Includes 52-Week Data [Read more]